Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer

Urologia Internationalis

Volumn 88, Issue 1, 2012, Pages 25-33

  Divrik, Rauf Taner ^a,h   Türkeri, Levent ^b   Şahin, Ali F ^c   Akdoǧan, Bülent ^d   Ateş, Ferhat ^e   Çal, Çaǧ ^f   Baltaci, Sümer ^g  

^a MH Tepecik Research and Training Hospital   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c Sivas Devlet Hastanesi   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

^e GULHANE SCHOOL OF MEDICINE   (Turkey)

^f EGE UNIVERSITY   (Turkey)

^g ANKARA UNIVERSITY   (Turkey)

^h Üroloji Kliniǧi ^*  (Turkey)

Author keywords

Androgen deprivation therapy; Bone metastasis; Castration resistance; Duration of response; Nadir PSA; Prostate cancer; Time to nadir PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOPSY; BONE METASTASIS; CANCER SIZE; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREMEDICATION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THERAPEUTICS; TIME FACTORS; TURKEY;

EID: 84856421020     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000334539     Document Type: Article

References (14)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
2. Walsh PC: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975;2:125-140.
3. Garnick MB: Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997;49(suppl): 5-15.
4. Landstrom M, Damber JE, Bergh A: Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Cancer Res 1994;54:4281-4284.
5. Hegarty NJ, Fitzpatrick JM, Richie JP, et al: Future prospects in prostate cancer. Prostate 1999;40:261-268.
6. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160:1220-1229.
7. Eisenberger MA, Carducci M: Treatment of hormone-refractory prostate cancer; in Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds): Campbell-Walsh Urology, ed 9, vol 3. Philadelphia, Saunders, 2007, pp 3101-3117.
8. Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-3990.
9. Collette L, de Reijke TM, Schroeder FH, et al: Prostate-specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003;44:182-189.
10. Collette L, Burzykowski T, Carroll KJ, et al: Is prostate-specific antigen a valid surrogate end-point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and Astra-Zeneca Pharmaceuticals. J Clin Oncol 2005;23:6139-6148.
11. Sim HG, Lau W K O, Cheng C W S: Predictors of androgen independence in metastatic prostate cancer. BJU Int 2004;93:1221-1224.
12. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE: Prognostic significance of the nadir prostatespecific antigen level after hormonal therapy for prostate cancer. J Urol 2002;168:995-1000.
13. Benaim EA, Pace CM, Lam PM, Roehrborn CG: Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002;59:73-78.
14. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM: Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997;158:160-163.